Cefotaxime: A reappraisal for use in lower respiratory tract infections
Abstract
Lower respiratory tract infections (LRTIs) are documented to cause significant morbidity and mortality in patients worldwide. During the ongoing pandemic, LRTIs like pneumonia are posing a major health concern for patients and the healthcare system. In COVID-19-related pneumonia bacterial co-infection is not uncommon and remains a leading cause of mortality in affected cases. Cefotaxime, a third-generation parenteral cephalosporin, has a broader spectrum of antimicrobial activity with a high-level of stability against β-lactamases. Despite many years of clinical usage for cefotaxime in LRTIs, resistance to this drug does not seem to be a major concern, and it is still one of the cornerstones in the choice effective antimicrobial therapy. This paper attempts to delineate available evidence for cefotaxime usage in various clinical situations like community acquired pneumonia (CAP), nosocomial pneumonia, acute exacerbations of chronic bronchitis (AECB) and acute bronchitis. This may be of help for a clinician to develop a thorough viewpoint on the rational use of this time-tested antimicrobial agent and to take an apt clinical decision towards the optimum patient care.
Read the paper
Related studies
- Impact of antibiotics on the human microbiome and consequences for host health
- Antibiotics in the clinical pipeline in October 2019
- The incidence of collagen-associated adverse events in pediatric population with the use of fluoroquinolones: a nationwide cohort study in Taiwan
- Research Communications of the 32nd ECVIM-CA Online Congress
- Singlet-Oxygen Therapy. Scientific And Methodological Materials
- Artificial Intelligence in Pharmacovigilance
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.